Advantages of Sequential or Bracketed Injection Methods to Improve the Chromatographic Analysis of Biotherapeutics
Brief intro:
- Author: Szabolcs Fekete, Mateusz Imiołek, Matthew Lauber
- Journal: LCGC International
- Publication Date: 2024 Jul 3
Products/Services used in the paper
Quotation shows PackGene:The Fluc mRNA/LNP was purchased from PackGene Biotech – Cap 1+N1meψUTP+LNP (Firefly Luciferase-mRNA-SM-102).
Research Field:Chromatographic Analysis of Biotherapeutics
Abstract
High-performance liquid chromatography (HPLC) analysis of biotherapeutics introduces new challenges because large molecules may require distinct injection modes or sample handling protocols to improve the analysis. Some challenges can be addressed by using autosampler methods that allow an analyst to program specific injection sequences. This article explores three case studies where autosampler injection programs help to (i) reduce the carry-over observed for large nucleic acids during anion-exchange chromatography (AEX), (ii) reduce peak distortion and breakthrough for monoclonal antibodies (mAbs) during hydrophilic-interaction chromatography (HILIC), and (iii) facilitate dissolution of lipid nanoparticles (LNPs) so that a size-exclusion chromatography (SEC) method can be applied for ribonucleic acid (RNA) payload analysis. The appropriate use of autosampler capabilities offers unique benefits to analyze biotherapeutics.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
